96428-50-1

基本信息
8-苯甲氧基-2-甲基咪唑[1,2-A]并吡啶-3-羧酸乙酯
2-甲基-8-(芐氧基)咪唑并[1,2-A]吡啶-3-甲酸乙酯
2-甲基-8-(苯基甲氧基)咪唑并[1,2-A]吡啶-3-羧酸乙酯
咪唑并[1,2-A]吡啶-3-羧酸2-甲基-8-(苯基甲氧基)-乙酯
Imidazo[1,2-a]pyridine-3-carboxylicacid, 2-methyl-8-(phenylm...
Ethyl 8-(Benzyloxy)-2-MethyliMidazo[1,2-a]pyridine-3-carboxylate
Ethyl 8-(benzyloxy)-2-MethylH-iMidazo[1,2-a]pyridine-3-carboxylate
ethyl 2-methyl-8-phenylmethoxyimidazo[1,2-a]pyridine-3-carboxylate
8-BENZYLOXY-2-METHYL-IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER
2-Methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester
Imidazo[1,2-a]pyridine-3-carboxylic acid, 2-methyl-8-(phenylmethoxy)-, ethyl ester
物理化學(xué)性質(zhì)
制備方法

24016-03-3

609-15-4
![2-甲基-8-(芐氧基)咪唑并[1,2-A]吡啶-3-甲酸乙酯](/CAS/GIF/96428-50-1.gif)
96428-50-1
實(shí)施例1A 8-(芐氧基)-2-甲基咪唑并[1,2-a]吡啶-3-羧酸乙酯的合成:將25g(124.8mmol)2-氨基-3-芐氧基吡啶溶解于781ml無水乙醇中,隨后加入102.7g(624.2mmol)2-氯乙酰乙酸乙酯和2湯匙4A分子篩。將反應(yīng)混合物加熱至回流(油浴溫度100℃),持續(xù)反應(yīng)2天。反應(yīng)完成后,將混合物濃縮,并在干冰冷卻條件下,通過旋轉(zhuǎn)蒸發(fā)器去除過量的2-氯乙酰乙酸乙酯。殘余物通過硅膠柱色譜法純化,流動相為環(huán)己烷:乙酸乙酯(梯度洗脫,比例從9:1至4:1)。最終得到20.81g目標(biāo)化合物2-甲基-8-(芐氧基)咪唑并[1,2-a]吡啶-3-甲酸乙酯,收率為54%,純度為99%。產(chǎn)物經(jīng)LC-MS(方法2)分析:保留時(shí)間Rt = 1.12min,質(zhì)譜(ESpos):m/z = 311(M + H)+。1H NMR(400MHz,DMSO-d6)數(shù)據(jù)如下:δ= 1.35(t,3H),2.59(s,3H),4.34(q,2H),5.32(s,2H),7.01-7.09(m,2H),7.33-7.48(m,3H),7.52(d,2H),8.81-8.86(m,1H)。
參考文獻(xiàn):
[1] Patent: US2014/128386, 2014, A1. Location in patent: Paragraph 0984; 0985; 0986; 0987; 0988
[2] Patent: US2014/128372, 2014, A1. Location in patent: Paragraph 0489; 0490; 0491; 0492; 0493
[3] Patent: US2017/57954, 2017, A1. Location in patent: Paragraph 0620; 0621; 0622; 0623; 0624
[4] Patent: US2016/347770, 2016, A1. Location in patent: Paragraph 0691; 0692; 0693; 0694; 0695
[5] Journal of Medicinal Chemistry, 1985, vol. 28, # 7, p. 876 - 892